In the previous issue of Breast Cancer Research, Lagadec and colleagues [1] used breast cancer cell line models to examine the self-renewal and cell cycle properties of cancer cells that survive during the course of fractionated sublethal radiation. Previous studies from the same group and others have demonstrated enrichment or resistance
of cancer-initiating cells (CICs) during the course of fractionated radiation [2, 3] . Th e current report demonstrates that the enriched CICs are capable of enhanced self-renewal for three generations compared with CICs from non-irradiated cells. Contrary to non-irradiated CICs, which are non-proliferating and are predominantly in the G 0 phase of the cell cycle, radiation mobilizes CICs from a quiescent to a proliferative state (G 2 phase). Whether CICs undergo similar cell cycle changes in vivo upon radiation and whether cycling CICs become susceptible to drugs targeting cells moving through G 2 phase remain to be determined.
Cancer cells expressing the cell surface marker CD44 but not CD24 (CD44 + /CD24 −/low ) were the fi rst described breast cancer CICs [4] . Subsequent studies have identifi ed additional phenotypic or functional markers or both to characterize CICs: elevated levels of aldehyde dehydrogenase (ALDH1 + ) [5] , lower levels of proteosome activity [6] , enhanced PKH26 dye-retaining capacity [7] , CD24 high /CD49F high /Delta-notch-like EGF (epidermal growth factor) repeat-containing transmembrane (DNER) high [7] , CD24 high /CD49F high /Delta-like 1 (DLL1) high [7] , CD49F + /DLL1 high /DNER high , and expression of a mammosphere signature, including low expression of claudin [8] −/low cells with low proteosome activity, although this specifi c subpopulation was not characterized further for stemness. Although these studies are beginning to refi ne CICs into distinct subgroups, the remaining question is which of the pheno typically distinct CICs are responsible for chemotherapy resistance and radiation resistance and organ-specifi c metastasis. Also, it is Abstract Identifi cation and characterization of cancer-initiating cells (CICs) enriched for stem cell-like functions and the establishment of a link between CICs and tumor recurrence, chemotherapy resistance and radiation resistance, and metastasis have been the focus of cancer research for the last eight years. Although this fi eld has its share of controversies, it is becoming apparent that cells isolated from recurrent or residual tumors or both are enriched for cancer cells that have a specifi c phenotype compared with heterogeneous cells in the primary tumor. Enrichment of CICs in tumors subjected to radiation therapy could be due in part to the delivery of sublethal doses of treatment and the effi cient radical scavenging system within CICs. Sublethal doses of radiation are suffi cient to induce senescence of non-CICs while forcing CICs to gain several new properties related to cell cycle progression in addition to maintaining or enhancing stem cell characteristics of pre-treatment CICs. Characterizing pathways responsible for the increase in CICs after therapy and exploiting the unique characteristics of therapy-resistant CICs for developing targeted therapies are becoming a central focus of research in the rapidly evolving fi eld of CICs. unclear whether the above markers can identify CICs for all intrinsic subtypes of breast cancer [9] or whether these markers favor characteriza tion of CICs derived from the basal subtype or the HER2 + subtype of breast cancer [10, 11] . CD44 + /CD24 −/low cells are generally enriched in basal subtype breast cancers as well as in cell lines that have undergone epithelial-to-mesenchymal transition [10, 12] . In contrast, luminal type breast cancers that express estrogen receptor-alpha (ERα) contain less than 1% CD44 [13] . However, the two cell lines diff er in their p53 mutation status; T47-D cells contain mutant p53, whereas p53 is wild-type in the MCF-7 cells [14] . Based on the previously described role of p53 in cancer stem cells in mouse models [15] , it is tempting to speculate that p53 status is one of the factors that determine the self-renewal capacity of cancer cells that survive a sublethal dose of radiation. It is important to emphasize that the enrichment of CICs was observed only upon exposure to a sublethal dose of radiation. Th erefore, similar enrichment of CICs may not occur in the clinical setting unless a signifi cant fraction of cancer cells receive a sublethal dose or contain a p53 mutation or both. In this respect, recent clinical trials have demon strated signifi cant survival benefi ts of radiation therapy for breast cancer patients [16] . Further optimization of radiation delivery to avoid exposure to sublethal doses may lead to increased benefi ts of radiation therapy. Abbreviations ALDH1, aldehyde dehydrogenase; CIC, cancer-initiating cell; DLL1, Delta-like 1; DNER, Delta-notch-like EGF (epidermal growth factor) repeat-containing transmembrane; ERα, estrogen receptor-alpha.
